Best Esmo Podcasts (2025)

1
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:57:51

14m ago1:57:51

1:57:51

Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.By Dr. Neil Love

1
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain 21:27

5d ago21:27

21:27

In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a leading expert in the field, to discuss the complexities surrounding the diagnosis of amyloidosis, including both the light chain and ATTR subtypes. The conversation covers early clinical signs that clinicians often overlook, key differenc…

1
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances 58:22

9d ago58:22

58:22

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.…

1
IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more 20:16

14d ago20:16

20:16

VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France. In today’s podcast episode, you will hear some highlights from the event from leading experts in the field of paroxysmal nocturnal hemoglobinuria (PNH). First, Jens Panse, MD, Aachen University Hospital, Aachen, Germa…

1
Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease 11:43

20d ago11:43

11:43

In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He…

1
Gene therapy in sickle cell disease: patient selection, potential complications, & more 21:19

27d ago21:19

21:19

In this episode of the VJHemOnc podcast you will hear from Akshay Sharma, MBBS, MSc, St. Jude Children’s Research Hospital, Memphis, TN, who takes a deep dive into gene therapy for the treatment of sickle cell disease (SCD). Dr Sharma begins by discussing the status of gene therapy in SCD, outlining considerations for clinicians when selecting pati…

1
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community 23:38

1M ago23:38

23:38

Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer …

1
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit 50:15

1M ago50:15

50:15

Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.By Dr. Neil Love

1
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy 19:49

1M ago19:49

19:49

This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations.…

1
Highlights from iwMyeloma 2025: trial updates and practical considerations 35:15

2M ago35:15

35:15

VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting. First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL…

1
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit 52:17

2M ago52:17

52:17

Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  CME information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:02

2M ago1:33:02

1:33:02

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment 34:35

2M ago34:35

34:35

In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice gui…

1
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more 22:53

2M ago22:53

22:53

In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantat…

1
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! 46:21

2M ago46:21

46:21

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hod…

1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor 57:28

2M ago57:28

57:28

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.By Dr. Neil Love

1
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms 18:06

3M ago18:06

18:06

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cel…

1
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! 23:26

3M ago23:26

23:26

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Can…

1
The VOICES of Black Women Study: Expanding Representation in Cancer Research 21:08

3M ago21:08

21:08

Black women have long been underrepresented in large-scale cancer studies, leaving critical gaps in our understanding of the factors influencing cancer risk and outcomes. The VOICES of Black Women Study, launched by the American Cancer Society, is leading efforts to close these gaps by examining a range of health and social determinants to better u…

1
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance 16:52

3M ago16:52

16:52

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients. In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, Unive…

1
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! 27:48

3M ago27:48

27:48

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and patient care, offering insights and strategies for healthcare professionals to address them. The discussion centers on four topics: the treatment of smoldering myeloma, managing frail and elderly patients, challenge…

1
The Power of Social Capital: Tackling Gender Inequalities in Academic Medicine 24:09

4M ago24:09

24:09

In this episode of CancerSpeak, host Dr. Ruth O’Regan, Deputy Editor and Breast Disease Section Editor of Cancer, is joined by Dr. Jennifer Grandis of the University of California San Francisco to discuss her team’s recent review article in Cancer on gender disparities in academic medicine. Tune in for a fascinating conversation between Dr. O’Regan…

1
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes 18:39

4M ago18:39

18:39

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel appro…

1
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! 13:15

4M ago13:15

13:15

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis fr…

1
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia 18:27

4M ago18:27

18:27

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts. First, Sophia Delicou, MD, H…

1
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 18:29

4M ago18:29

18:29

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Cen…

1
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 1:00:02

4M ago1:00:02

1:00:02

Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here…

1
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML 28:59

5M ago28:59

28:59

In this podcast, we bring you exclusive updates on acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/…

1
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! 22:21

5M ago22:21

22:21

This podcast episode covers key highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The Univ…

1
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting 31:20

5M ago31:20

31:20

Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia …

1
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS 19:02

5M ago19:02

19:02

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS). You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park,…

1
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more! 16:31

5M ago16:31

16:31

VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL). You…

1
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents 28:52

6M ago28:52

28:52

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth explo…

1
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer 48:03

6M ago48:03

48:03

Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer 58:47

6M ago58:47

58:47

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.By Research To Practice

1
Improving care for patients with SCD: pain management, ongoing projects & unmet needs 16:45

7M ago16:45

16:45

This week's podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT 2024), which was held in London, UK. You will hear from Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, Subarna Chakravorty, MB…

1
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care 34:43

7M ago34:43

34:43

In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN…

1
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences 1:00:12

7M ago1:00:12

1:00:12

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.By Research To Practice

1
CHIP, mCAs, and Cancer Risk: What We’re Learning 21:19

7M ago21:19

21:19

CANCER Section Editor and Host Dr. Courtney DiNardo welcomes Dr. Pinkal Desai, Dr. Koichi Takahashi, and Ms. Nehali Shah to discuss new research on the impact of clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) on the risk and mortality of solid tumors like breast, lung, and colorectal cancer. Dr. Des…

1
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more! 21:36

7M ago21:36

21:36

Today's podcast episode focuses on the management of complications associated with Waldenström's macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK…

1
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer 1:05:42

7M ago1:05:42

1:05:42

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024 24:59

7M ago24:59

24:59

This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel,…

1
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences 54:40

8M ago54:40

54:40

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.By Research To Practice

1
Key Highlights from ESMO 2024 – Shaping the Future of Clinical Oncology 25:13

8M ago25:13

25:13

In this special edition of CancerSpeak, CANCER Editor-in-Chief Dr. Suresh Ramalingam is joined by Dr. Gil Morgan (Social Media Editor for CANCER), Dr. Jason Luke (Melanoma and Skin Section Editor for CANCER), and patient advocate Deborah Collyar to discuss key takeaways from the European Society for Medical Oncology (ESMO) 2024 Congress. From advan…

1
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS 22:39

8M ago22:39

22:39

This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The Universit…

1
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events 9:29

8M ago9:29

9:29

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, H…

1
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review 42:46

8M ago42:46

42:46

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.By Research To Practice

1
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! 16:34

8M ago16:34

16:34

Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help…

1
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:08

8M ago1:00:08

1:00:08

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.…

1
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 20:30

8M ago20:30

20:30

Today's podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster,…

Podcasts Worth a Listen

Esmo Podcasts

Podcasts Worth a Listen

Quick Reference Guide